Effects of prosthesis-patient mismatch on cardiac function and clinical outcome after transcatheter aortic valve implantation-Reference-Cited by-同舟云学术

Effects of prosthesis-patient mismatch on cardiac function and clinical outcome after transcatheter aortic valve implantation

Published:2024-08-19 Issue:0 Volume:0 Page:
ISSN:2734-6382
Container-title:Romanian Journal of Cardiology
language:en
Short-container-title:

Author:

Parasca Catalina A.¹²,Calin Andreea¹²,Rosca Monica¹²,Botezatu Simona¹²,Enache Roxana¹²,Beladan Carmen¹²,Deleanu Dan²,Chioncel Ovidiu¹²,Bubenek-Turconi Serban¹²,Iliescu Vlad A.¹²,Popescu Bogdan A.¹²

Affiliation:

1. University of Medicine and Pharmacy “Carol Davila” , Bucharest , Romania

2. Emergency Institute for Cardiovascular Diseases “Prof. Dr. C. C. Iliescu” , Bucharest , Romania

Abstract

Abstract Background Transcatheter aortic valve implantation (TAVI) prostheses have better hemodynamics compared to surgical prostheses, with a lower incidence of prosthesis-patient mismatch (PPM). Nonetheless, the effects of PPM have been controversial regarding clinical impact. This study aims to determine the short-term impact of PPM on cardiac function and the effect of PPM on mid-term outcome in patients undergoing transfemoral TAVI with balloon-expandable valves. Methods One hundred sixty consecutive patients (76.5±7.4 years, 85 men) were enrolled and examined before and 30 days after TAVI, by comprehensive echocardiogram (speckle tracking echocardiography and strain analysis). Patients were divided according to measured PPM (PPMM) into PPMM group: indexed effective orifice area (EOAi)≤0.85 cm2/m2 (n=64), and No-PPMM group: EOAi>0.85 cm2/m2 (n=96). Predictors and predictive value of PPMM were analyzed based on the primary endpoint, 3-year all-cause mortality. Results Impaired LA function was independently associated with PPMM after TAVI (global LA strain - OR 0.92, p = 0.022). Three-year mortality was higher in the PPMM group (23.4% vs. 10.4% in the No-PPMM group, p=0.026). Conclusions Our study revealed significantly worse impairment of LA function in patients with PPMM compared to those without PPMM on short-term follow-up, which correlated with 3-year mortality.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/rjc-2024-0022

Reference45 articles.

1. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019; 380:1706–1715. doi:10.1056/NEJMoa1816885.

2. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, et al. Transcatheter aorticvalve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019; 380:1695–1705. doi:10.1056/NEJMoa1814052.

3. Braghiroli J, Kapoor K, Thielhelm TP, Ferreira T, Cohen MG. Transcatheter aortic valve replacement in low risk patients: A review of PARTNER 3 and Evolut low risk trials. Cardiovascular Diagnosis and Therapy 2020. doi:10.21037/cdt.2019.09.12.

4. Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, Takkenberg JJ, David TE, Butchart EG, Adams DH, et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 2008; 135:732–738. doi:10.1016/j.jtcvs.2007.12.002.

5. Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, Modine T, Lancellotti P, Sondergaard L, Ludman PF, Tamburino C, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: A consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017; 38:3382–3390. doi:10.1093/eurheartj/ehx303.